Skip to main content
Premium Trial:

Request an Annual Quote

Anil Singhal, Edward Tenthoff, Muzammil Mansuri

Premium

Anil Singhal has become chief drug development officer of Martinsried, Germany-based Xerion Pharmaceuticals. He will be based in the company’s Cambridge, Mass., office. Previously, he was vice president at Light Sciences and Pacific Pharmaceuticals, where he led oncology programs through preclinical and clinical stages of development.

 

Edward Tenthoff has joined U.S. Bancorp Piper Jaffray as a senior research analyst on the genomics sector. Tentoff comes to Piper Jaffray from Think Equity Partners, where he also covered genomics and biotechnology companies. Prior to this, Tenthoff covered biotechnology as a senior research analyst at the now-defunct firm Robertson Stephens.

 

Muzammil Mansuri, executive-in-residence at Flagship Ventures, has been appointed to the scientific advisory board of Achillion Pharmaceuticals. Mansuri is currently chairman of Beyond Genomics, and a director and executive chairman of Adaptive Therapeutics. He has previously served as executive vice president and chief operating officer at GPC Biotech. Between 1994 and 2000, Mansuri also held executive positions at Mitotix. Prior to this time, he worked at Bristol-Myers Squibb.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.